MX2022005973A - Inhibidores de akt para mejorar la persistencia de celulas t quimericas. - Google Patents
Inhibidores de akt para mejorar la persistencia de celulas t quimericas.Info
- Publication number
- MX2022005973A MX2022005973A MX2022005973A MX2022005973A MX2022005973A MX 2022005973 A MX2022005973 A MX 2022005973A MX 2022005973 A MX2022005973 A MX 2022005973A MX 2022005973 A MX2022005973 A MX 2022005973A MX 2022005973 A MX2022005973 A MX 2022005973A
- Authority
- MX
- Mexico
- Prior art keywords
- car
- cells
- subject
- persistence
- akt inhibitors
- Prior art date
Links
- 239000003197 protein kinase B inhibitor Substances 0.000 title abstract 4
- 230000002688 persistence Effects 0.000 title abstract 3
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 229940126638 Akt inhibitor Drugs 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 238000011357 CAR T-cell therapy Methods 0.000 abstract 1
- 230000008034 disappearance Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La recaída en la transferencia de células adoptivas de células CAR-T es a menudo el resultado de la desaparición de las células CAR-T. En el presente documento se describe un método para mejorar la terapia con células CAR-T en un sujeto, que comprende administrar a un sujeto que experimenta una transferencia celular adoptiva de células CAR-T terapéuticas un inhibidor de Akt en una cantidad eficaz para aumentar la persistencia de las células CAR-T. Como consecuencia, un sujeto tratado con una combinación de células CAR-T y un inhibidor de Akt tiene menos probabilidades de recaer. Por lo tanto, también se describe en el presente documento un método para tratar a un sujeto, que comprende transferir de forma adoptiva al sujeto una cantidad eficaz de una composición que comprende una célula CAR-T y administrar al sujeto un inhibidor de Akt en una cantidad eficaz para aumentar la persistencia de las células CAR-T.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962937028P | 2019-11-18 | 2019-11-18 | |
| US201962937359P | 2019-11-19 | 2019-11-19 | |
| US201962942662P | 2019-12-02 | 2019-12-02 | |
| US201962944295P | 2019-12-05 | 2019-12-05 | |
| US202062982480P | 2020-02-27 | 2020-02-27 | |
| PCT/US2020/061107 WO2021102038A1 (en) | 2019-11-18 | 2020-11-18 | Akt inhibitors for enhancing chimeric t cell persistence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005973A true MX2022005973A (es) | 2022-09-09 |
Family
ID=75981019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005973A MX2022005973A (es) | 2019-11-18 | 2020-11-18 | Inhibidores de akt para mejorar la persistencia de celulas t quimericas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230039099A1 (es) |
| EP (1) | EP4061383A4 (es) |
| JP (1) | JP2023503061A (es) |
| KR (1) | KR20220130100A (es) |
| CN (1) | CN115175686A (es) |
| AU (1) | AU2020387407A1 (es) |
| BR (1) | BR112022009607A2 (es) |
| CA (1) | CA3162094A1 (es) |
| IL (1) | IL293094A (es) |
| MX (1) | MX2022005973A (es) |
| WO (1) | WO2021102038A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117479949A (zh) * | 2021-05-19 | 2024-01-30 | 预见疗法有限公司 | 产生改进的免疫细胞的群体的方法 |
| CN113943710B (zh) * | 2021-09-17 | 2023-03-24 | 浙江大学医学院附属第一医院 | 一种car-t细胞培养用的培养基及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016341966A1 (en) * | 2015-10-20 | 2018-05-10 | Kite Pharma, Inc. | Methods of preparing T cells for T cell therapy |
| US11479755B2 (en) * | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
-
2020
- 2020-11-18 JP JP2022529041A patent/JP2023503061A/ja active Pending
- 2020-11-18 IL IL293094A patent/IL293094A/en unknown
- 2020-11-18 BR BR112022009607A patent/BR112022009607A2/pt unknown
- 2020-11-18 CN CN202080093576.0A patent/CN115175686A/zh active Pending
- 2020-11-18 CA CA3162094A patent/CA3162094A1/en active Pending
- 2020-11-18 EP EP20890010.0A patent/EP4061383A4/en active Pending
- 2020-11-18 KR KR1020227020788A patent/KR20220130100A/ko unknown
- 2020-11-18 AU AU2020387407A patent/AU2020387407A1/en active Pending
- 2020-11-18 MX MX2022005973A patent/MX2022005973A/es unknown
- 2020-11-18 US US17/756,138 patent/US20230039099A1/en active Pending
- 2020-11-18 WO PCT/US2020/061107 patent/WO2021102038A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022009607A2 (pt) | 2022-10-18 |
| EP4061383A1 (en) | 2022-09-28 |
| WO2021102038A1 (en) | 2021-05-27 |
| JP2023503061A (ja) | 2023-01-26 |
| AU2020387407A1 (en) | 2022-07-07 |
| IL293094A (en) | 2022-07-01 |
| CA3162094A1 (en) | 2021-05-27 |
| EP4061383A4 (en) | 2024-03-27 |
| CN115175686A (zh) | 2022-10-11 |
| US20230039099A1 (en) | 2023-02-09 |
| KR20220130100A (ko) | 2022-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023007193A (es) | Inhibidores de enpp1 y su uso para el tratamiento del cancer. | |
| MX2022001199A (es) | Compuestos de urea, amida y heteroarilo sustituido para la inhibicion de cbl-b. | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| MX2022005973A (es) | Inhibidores de akt para mejorar la persistencia de celulas t quimericas. | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| MX2021013751A (es) | Compuestos de ciano ciclobutilo para la inhibicion del protooncogen b de linfoma de linaje b de casitas (cbl-b) y usos de los mismos. | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| RS20050802A (en) | Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2022013417A (es) | Inhibidores de fosfatidilinositol 3 cinasa (pi3k) alfa y metodos de uso de los mismos. | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX2021016049A (es) | Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas. | |
| MX2021008943A (es) | Metodos para mitigar la lesion hepatica y promover la hipertrofia hepatica, la regeneracion e injerto celular en conjunto con tratamientos de radiacion y/o radiomimeticos. | |
| MX2022001933A (es) | Inhibidores de enzimas. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
| MX2022002069A (es) | Inhibidores de enzimas. | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| MX2023006542A (es) | Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo. | |
| MX2021008305A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. | |
| WO2023220131A3 (en) | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | |
| MX2021006706A (es) | Inhibidores de óxido sintasa neuronal para inmunoterapia. |